GlycoMark (1,5-AG): How to Interpret Your Result

What GlycoMark measures

1,5-AG is a naturally occurring compound measured in blood. Its concentration is related to kidney reabsorption and can decrease when urinary glucose handling changes. Basic research has identified renal transport pathways relevant to 1,5-AG handling. PubMed Because glucose levels, kidney function, medications, and other clinical factors can affect the result, GlycoMark should be treated as a context-dependent biomarker rather than a direct readout of every meal or a score that must be pushed upward.

The familiar explanation, that a low value means blood glucose has crossed one fixed “renal threshold,” is too simple for an individual result. Renal glucose handling varies between people and can change with kidney disease, pregnancy, age, and medicines. A laboratory report does not observe glucose continuously, so it cannot show exactly when an excursion occurred, what caused it, or how a person would respond to a specific diet or medication change.

The testing laboratory provides the result, units, and reference interval that apply to its assay. Do not compare a value with a cutoff from another assay, a wellness blog, or a screenshot. A clinician may decide that a result is not interpretable in the current setting or that a different glucose measurement is more useful.

How it fits with standard diabetes assessment

Diabetes screening and management use validated methods selected for the clinical question, such as A1C, plasma glucose testing, self-monitored glucose, or continuous glucose monitoring when appropriate. GlycoMark does not replace any of them. A normal result does not rule out diabetes or hypoglycemia; a low result does not establish that a person has diabetes, that a particular food is responsible, or that a medicine should be increased.

The American Association of Clinical Endocrinology’s diabetes algorithm describes individualized use of glycemic assessment and treatment rather than a one-marker approach. PubMed A broader guideline cannot turn 1,5-AG into a stand-alone treatment target. The clinician needs to consider the person’s symptoms, diagnosis, medication regimen, safety risks, and other glucose data.

Medicines and kidney function can make the result misleading

Kidney function is essential context for 1,5-AG. The marker depends on renal filtration and reabsorption, so kidney disease or a condition affecting renal glucose handling can reduce confidence in the usual interpretation. Research on inherited defects in this pathway illustrates that renal handling can change the concentration independently of ordinary glucose assessment. PubMed A clinician may decide not to use the result for glycemic assessment in that setting.

SGLT2 inhibitors deserve special attention. These medicines intentionally increase urinary glucose excretion. That mechanism can alter 1,5-AG independently of a person’s ordinary glucose pattern, so an online “spike detector” interpretation can be misleading. Never stop or change an SGLT2 inhibitor, insulin, metformin, or another diabetes medicine because of a single GlycoMark result. Ask the prescribing clinician or pharmacist how the medicine affects the test.

Pregnancy, acute illness, and changes in diet or hydration can also alter how a laboratory result should be interpreted. If the result conflicts with A1C, home readings, or continuous-monitoring data, the discrepancy is a reason to investigate context, not to assume that one test is automatically correct.

What a low result does and does not mean

A result below the laboratory interval may prompt a clinician to look at recent glycemic information and at factors affecting renal handling. It is not a diagnosis of “post-meal spikes,” insulin resistance, poor adherence, or dietary failure. It also does not validate a personalized food list, supplement regimen, fasting schedule, or exercise rule.

The best next step depends on why the test was ordered. A person with known diabetes may benefit from reviewing current glucose information, medication adherence, side effects, and the treatment plan. A person without diagnosed diabetes may need standard diagnostic testing if a clinician thinks symptoms or risk factors warrant it. The laboratory result alone cannot choose between those paths.

What a high or in-range result means

An in-range result should not be used as a certificate that glucose control is “good” or that complications are impossible. It does not capture every glucose pattern and may be affected by the same kidney and medication factors that complicate a low value. A person can have a value within an interval and still need attention to A1C, fasting glucose, symptoms, or other clinical concerns.

Similarly, there is no safe universal instruction to “raise” 1,5-AG with a supplement or food. The meaningful target is appropriate glucose management for the individual’s condition, not manipulation of a surrogate marker.

Questions to bring to the follow-up visit

Ask why the test was ordered, which reference interval applies, and whether kidney function or a medicine affects interpretation. Ask whether A1C, plasma glucose, home readings, or continuous monitoring are needed to answer the real clinical question. If a treatment change is proposed, ask what data support it and how hypoglycemia or other adverse effects will be avoided.

Bring every prescription, over-the-counter product, and supplement. That is particularly important for diabetes medicines and kidney-related treatment. A pharmacist can identify whether a medicine changes urinary glucose handling or has administration instructions that need to be followed.

Diet, activity, and “spike” claims

Regular activity and balanced eating patterns can be part of evidence-based diabetes care, but a single 1,5-AG result cannot prescribe a meal plan, a supplement, or a specific number of post-meal walks. A review of standing and light walking may be relevant to cardiometabolic health in general, but it does not validate GlycoMark as a diagnostic or treatment-directing test. PubMed

If a clinician recommends changes in food or activity, they should fit the person’s diabetes type, medications, nutritional needs, mobility, and risk of low glucose. Someone taking insulin or a sulfonylurea should not make major changes without discussing safety with the prescribing team.

When to seek prompt care

Seek urgent care for symptoms that may indicate severe hyperglycemia, hypoglycemia, dehydration, or another emergency, including confusion, fainting, chest pain, severe vomiting, trouble breathing, or inability to keep fluids down. Do not wait for a repeat GlycoMark test. For routine questions, contact the clinician managing diabetes or kidney care.

Bottom line

GlycoMark is a supplementary laboratory marker, not a diagnosis, a universal glucose threshold, or a self-treatment guide. Interpret it using the performing laboratory’s range and the full clinical picture, especially kidney function and medicines that affect urinary glucose. The right goal is safe diabetes care based on validated measurements and individualized clinical judgment.